Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
February 06, 2019 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
January 30, 2019 07:00 ET
|
Eyenovia, Inc.
MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet™ platform delivery technology ...
Eyenovia Prices Public Offering of Common Stock
December 19, 2018 09:05 ET
|
Eyenovia, Inc.
NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose...
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
December 03, 2018 09:00 ET
|
Eyenovia, Inc.
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study and enrolled the first patient in its...
Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability
November 28, 2018 16:05 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high...
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
November 26, 2018 09:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...
Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis
November 13, 2018 07:30 ET
|
Eyenovia, Inc.
Company on track to initiate Phase III trials in late November NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of...
Eyenovia Reports Third Quarter 2018 Financial Results
November 13, 2018 06:30 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia Announces Conference Call and Webcast for Third Quarter 2018 Financial Results
November 01, 2018 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...
Eyenovia to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2018
October 23, 2018 09:00 ET
|
Eyenovia, Inc.
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology...